Iksuda Therapeutics
1 known investors
Iksuda develops antibody-drug conjugates (ADCs) with tumor-selective payload release and activation, targeting difficult-to-treat cancers. It has a clinical-stage pipeline and a proprietary protein alkylating payload class called ProAlk, and works with research institutions and industry partners on ADC design and development.
Investors · 1
In the news
Frequently asked questions
- What does Iksuda Therapeutics do?
- Iksuda develops antibody-drug conjugates (ADCs) with tumor-selective payload release and activation, targeting difficult-to-treat cancers. It has a clinical-stage pipeline and a proprietary protein alkylating payload class called ProAlk, and works with research institutions and industry partners on ADC design and development.
- Who are Iksuda Therapeutics's investors?
- Iksuda Therapeutics's investors include Premier Partners.